Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
ASX healthcare share undervalued post earnings
Short term headwinds mask long term value opportunity.
stocks
ASX energy share sees 363% increase in dividend
Geopolitical tensions drive strong profit and dividends for oil refiner.
stocks
Wide moat share remains cheap despite rising costs
Higher costs weigh on profits but stronger sales trends support long term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,373.40 | 19.90 | -0.21% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,744.52 | 233.42 | 0.91% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 66,227.55 | 371.12 | 0.56% |
| NZX 50 Index | 14,034.36 | 41.64 | 0.30% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,164.80 | 18.90 | -0.21% |
| SSE Composite Index | 3,909.48 | 20.03 | 0.52% |